The
U.S. Food and Drug Administration (FDA) has announced that it is scaling back
the number of routine quality inspections it plans to conduct in the U.S. each
year by 40 percent. Instead the FDA will undertake more inspections overseas.
The
change has taken place because of FDA concerns with imported medications. The
FDA plans to conduct 591 good manufacturing practice (GMP) inspections in
fiscal 2014 and 2015 in the U.S. This is down from the 967 performed during
2013-2014. In place, the FDA is aiming to perform 30 percent more foreign GMP
inspections, conducting 843 inspections each year. Companies will be chosen for
inspection based on the agency’s risk-based inspection model that grants leeway
to high-quality companies.
Posted by Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources